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Chronic obstructive pulmonary disease (COPD) is a complex and heritable disease,
associated with multiple genetic variants. Specific familial types of COPD may be
explained by rare variants, which have not been widely studied. We aimed to discover
rare genetic variants underlying COPD through a genome-wide linkage scan. Affected-
only analysis was performed using the 6K Illumina Linkage IV Panel in 142 cases
clustered in 27 families from a genetic isolate, the Erasmus Rucphen Family (ERF) study.
Potential causal variants were identified by searching for shared rare variants in the
exome-sequence data of the affected members of the families contributing most to the
linkage peak. The identified rare variants were then tested for association with COPD in
a large meta-analysis of several cohorts. Significant evidence for linkage was observed
on chromosomes 15q14–15q25 [logarithm of the odds (LOD) score = 5.52], 11p15.4–
11q14.1 (LOD = 3.71) and 5q14.3–5q33.2 (LOD = 3.49). In the chromosome 15 peak,
that harbors the known COPD locus for nicotinic receptors, and in the chromosome 5
peak we could not identify shared variants. In the chromosome 11 locus, we identified
four rare (minor allele frequency (MAF) <0.02), predicted pathogenic, missense variants.
These were shared among the affected family members. The identified variants localize
to genes including neuroblast differentiation-associated protein (AHNAK), previously
associated with blood biomarkers in COPD, phospholipase C Beta 3 (PLCB3), shown
to increase airway hyper-responsiveness, solute carrier family 22-A11 (SLC22A11),
involved in amino acid metabolism and ion transport, and metallothionein-like protein 5
(MTL5), involved in nicotinate and nicotinamide metabolism. Association of SLC22A11
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and MTL5 variants were confirmed in the meta-analysis of 9,888 cases and 27,060
controls. In conclusion, we have identified novel rare variants in plausible genes related
to COPD. Further studies utilizing large sample whole-genome sequencing should
further confirm the associations at chromosome 11 and investigate the chromosome
15 and 5 linked regions.
Keywords: COPD, genetic linkage analysis, genetic isolate, rare variants, chromosome 11
INTRODUCTION
Chronic obstructive pulmonary disease is a common and
complex disease, and one of the leading causes of death
worldwide (Lozano and Naghavi, 2012). Previous studies
provided heritability estimates for COPD of 20% to even 60%
(Ingebrigtsen et al., 2010; Zhou et al., 2013). Both rare variants
with a large impact and common variants with a modest impact
on the risk to develop COPD have been identified. The SERPINA1
gene at chromosome 14q32.13, encoding AAT, was in fact the
first gene identified to be associated with COPD (Laurell and
Eriksson, 1963; Bashir et al., 2016). Rare variants in SERPINA1
are known to contribute to COPD risk in AAT deficiency in
homozygous and heterozygous carriers of the low-frequency
Z allele (Foreman et al., 2017). In an exome study of severe,
early-onset families, Qiao et al. (2016) identified several genes
with rare variants segregating in at least two pedigrees. In
extended families, genetic linkage studies have found evidence of
linkage to chromosomes 2q, 6q, 8p, 12p, and 19q, among others
(Silverman et al., 2002; Palmer et al., 2003). However, many
initially promising findings from linkage or exome sequencing
in candidate-gene studies could not be replicated in subsequent
analyses (Hersh et al., 2005).
Common variants in several genes have been identified in
multiple GWAS, to be associated with COPD or obstructive
lung function impairment. Among consistently replicated loci
in GWAS are genes on chromosome 4 – Hedgehog-interacting
protein (HHIP) and Family with sequence similarity 13 member
A (FAM13A), chromosome 5 – 5-hydroxytryptamine receptor
4 (HTR4), chromosome 15 – Nicotinic cholinergic receptors
(CHRNA3/5) and Ion-responsive element binding protein 2
(IREB2) and chromosome 19 – Cytochrome P450 family gene
(CYP2A6), member RAS oncogene family gene (RAB4B) and Egl-
9 family hypoxic-inducible factor 2 (EGLN2) (Hobbs et al., 2017;
Wain et al., 2017). However, only few loci identified in GWAS
could be functionally explained.
Despite the undeniable progress in understanding the genetic
origins of COPD, a major part of its heritability remains
unexplained. A complicating factor in studies on the genetics
Abbreviations: AAT, Alpha-1-antitrypsin; ATS, American thoracic society;
CADD, Combined Annotation Dependent Depletion; COPD, chronic obstructive
pulmonary disease; CT, computed tomography scan; ERF, Erasmus Rucphen
Family; ERS, European Respiratory Society; FEV1, forced expiratory volume
in one second; FVC, forced vital capacity; GoNL, genome of the Netherlands;
GWAS, genome-wide association study; HLOD, heterogeneity log of odds score;
HRC, haplotype reference consortium; KEGG, Kyoto Encyclopedia of Genes and
Genomes; LLS, lifelines study; LOD, logarithm of the odds; MAF, minor allele
frequency; OATs, organic anion transporters; QC, quality control; RS, Rotterdam
Study; SNVs, single nucleotide variants; VlaVla, Vlagtwedde/Vlaardingen-study.
of COPD is that COPD is considered a complex genetic trait,
i.e., multiple, possibly interacting, genetic and environmental
factors are involved. Therefore, there is a need for fine mapping
techniques that can identify functional, rare variants with
large effects explaining specific types of COPD. Rare variant
association studies can be carried out in relatively small sample
sizes when using family-based settings (Auer and Lettre, 2015).
In a genetically isolated population, alleles that are found at
low or very-low (rare) frequencies in control samples may
reach much higher proportions due to a limited number of
founder individuals, genetic drift, minimal immigration, and
high inbreeding (Pardo et al., 2005). Therefore, attempting
to identify risk genes for COPD in populations that are
relatively genetically and environmentally homogeneous could be
beneficial (Van Diemen et al., 2010).
This study uses the ERF study, a Dutch genetically isolated
population, to localize and identify rare genetic variants and
subsequently shows the relevance of these variants in the general
population by performing an association analysis in a large
sample.
MATERIALS AND METHODS
Study Populations
Linkage Study
The linkage study was performed in 142 related participants
from the ERF study. ERF is a family-based cohort study, studied
as part of the Genetic Research in Isolated Population (GRIP)
program. It is based in a genetically isolated community from
the south-west area of the Netherlands, set up to investigate
genes underlying different quantitative traits and common
diseases (Pardo et al., 2005). The participants of ERF are
living descendants of 22 couples from the religious isolate in
the 19th century, who had at least six children baptized in
the community church. The baseline data collection for over
3,000 people was conducted between June 2002 and February
2005. These individuals are related to each other through
multiple lines of descent in a single large pedigree spanning 23
generations and connecting over 23,000 individuals. In 2015 a
follow-up data collection for 1,500 participants was performed
by reviewing general practitioner’s records, including letters
from the specialists and spirometry reports and medication
use. In total 192 probable COPD cases were identified in the
follow-up. The COPD diagnosis was confirmed by respiratory
specialists based on an obstructive lung function, i.e., the ratio
of Forced Expiratory Volume in one second over the Forced
Vital Capacity (FEV1/FVC) < 0.7, with or without medication
Frontiers in Genetics | www.frontiersin.org 2 April 2018 | Volume 9 | Article 133
fgene-09-00133 April 17, 2018 Time: 18:35 # 3
Nedeljkovic et al. Genetic Linkage Study of COPD
use (n = 116). If the information on FVC was missing (n = 14),
the following criteria for COPD were used: FEV1 < 80%, use
of respiratory medication and a COPD diagnosis in the report
of the respiratory specialist to the general practitioner. If no
lung function measurement was available (n = 15), COPD
diagnosis was based on: medication use with CT-scan of the
lungs indicating COPD and/or a history of frequent COPD
exacerbations mentioned in the medical documents. Thus, the
COPD diagnosis could be confirmed for 145 participants, of
which 3 did not have genotyping data, resulting in the final
sample size for the linkage study of 142 COPD cases.
Association Study
The association analysis was performed using data from the RS
(1,588 cases and 9,784 controls), the LLS (1,647 cases and 9,530
controls), the VlaVla study (375 cases and 1,019 controls) and
the data from the study of Hobbs et al. (2016) (6,161 cases and
6,004 controls), in addition to the ERF study (117 cases and 1,091
controls).
Rotterdam Study is a prospective, population-based study
(Ikram et al., 2017), focusing on the diseases in the participants
aged 45 or older. The COPD diagnosis in the RS was
defined as having pre-bronchodilator obstructive spirometry
(FEV1/FVC < 0.7), assessed either by spirometry in the
research center or by reviewing medical histories of the
participants. Spirometry was performed by trained paramedical
personnel, according to the guidelines of the American Thoracic
Society/European Respiratory Society (ATS/ERS). In absence of
interpretable spirometry measures, all medical information of
subjects regularly using respiratory medication was reviewed,
including files from specialists and general practitioners, to
confirm a diagnosis of COPD. Both ERF and RS have been
approved by the Medical Ethics Committee of the Erasmus
Medical Center. All participants provided written informed
consent to participate in the study and to obtain information
from their treating physicians.
Lifelines study is a multi-disciplinary prospective population-
based cohort of the Northern provinces of the Netherlands with
a three generation design, focusing on the onset of common
complex diseases (Scholtens et al., 2015). COPD was defined
as having pre-bronchodilator FEV1/FVC < 0.7, assessed by
spirometry using a Welch Allyn Version 1.6.0.489, PC-based
SpiroPerfect with Ca Workstation software. All subjects provided
written informed consent and the study was approved by the
Medical Ethics Committee of the University Medical Center
Groningen, Groningen, Netherlands.
The VlaVla is a prospective, Dutch population-based cohort
including individuals from Vlagtwedde (a rural area) and
Vlaardingen (an urban area), aimed to gain insight into the
risk factors for chronic airway diseases and lung function
(Van Diemen et al., 2005). COPD was defined as having pre-
bronchodilator FEV1/FVC < 0.7. Data of the last survey in
1989/1990 were used and spirometry data were collected by
performing a slow inspiratory maneuver, using a water-sealed
spirometer (Lode instruments, Groningen, Netherlands). The
Committee on Human Subjects in Research of the University
of Groningen reviewed the study and affirmed the safety of the
protocol and study design and all participants gave their written
informed consent.
In the study by Hobbs et al. (2016) COPD cases were defined as
having FEV1/FVC≤ 0.7 and FEV1≤ 80% of the predicted value.
It was multi-ethnic study with Asian, African, and European
ancestry individuals. Institutional review board approval and
written informed consent were obtained for all these cohorts. For
more details please refer to their publication (Hobbs et al., 2016).
Genotyping
DNA Isolation
For all participants, DNA was extracted from venous blood using
the salting out method (Miller et al., 1988).
Linkage Array
For the linkage analysis genotyping was performed using the
6K Illumina Linkage IV panel (Illumina, San Diego, CA,
United States). Further, QC was performed involving exclusion
of the variants with call rate<98%, those diverging from Hardy–
Weinberg equilibrium (P < 10−8) and X-chromosome variants
and participants with an overall call rate <96%. Mendelian
inconsistencies were designated as missing genotypes. The final
dataset comprised 5,250 autosomal SNVs in 3,018 participants.
Exome-Sequencing and Genotyping
The sequencing and genotyping in the ERF study have been
described elsewhere (Amin et al., 2017). In short, for 1,336
ERF participants whole exome sequencing was performed at a
mean depth of 74× (Agilent, v4 capture). After QC, 543,954
SNVs in 1,327 participants were retained. For 1,527 individuals
whose exomes were not sequenced, the Illumina Infinium
HumanExome BeadChip v1.1 was used for genotyping and
variant calling was done using Genome Studio. After QC 70,000
polymorphic SNVs in 1,515 participants were retrieved. Of these,
the overlap with COPD status information was available for 636
participants (59 cases and 577 controls) with exome-sequence
and 572 participants (58 cases and 514 controls) with exome-
chip data. The cases overlap with the sample used in the linkage
analysis. The ERF data is available in the EGA public repository1
with ID number: EGAS00001001134.
The RS was genotyped using Illumina 550K and Illumina
610K and 660K arrays, and genotyping QC was done as
described elsewhere (Iglesias et al., 2017). HRC imputation panel
(McCarthy et al., 2015) was used for imputation. File preparation
and imputation was done as described elsewhere (Iglesias et al.,
2017). In the final dataset we included 11,372 participants of RS
(cases and controls) with HRC imputed genotype data available.
In LLS and VlaVla the genotyping was done using Illumina
CytoSNP-12 arrays and QC was done as described elsewhere (De
Jong et al., 2015). The GoNL panel was used for imputation of
LLS and VlaVla and was done as described elsewhere (Scholtens
et al., 2015). The final dataset included 11,177 participants of LLS
and 1,394 of VlaVla.
In Hobbs et al. (2016) work all individuals were genotyped
using the Illumina HumanExome arrays (v1.1 and v1.2; Illumina,
1https://www.ebi.ac.uk/ega/home
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San Diego, CA, United States). For more information please refer
to their publication (Hobbs et al., 2016).
Statistical Analyses
Genome-Wide Linkage Analysis
For the genome-wide linkage analysis, 142 related COPD
cases from ERF were used. The cases were linked in a
single large pedigree of 23 generations. However, due to the
linkage software restraints, the cases were clustered into 27
smaller (≤24 bits) families using PEDCUT software (Liu et al.,
2008). We used HaploPainter (Thiele and Nürnberg, 2005)
to illustrate all 27 pedigrees (Supplementary Figure S1). We
then performed affected-only parametric linkage analysis in
MERLIN software (Abecasis et al., 2002) using incomplete
penetrance and no phenocopies for both dominant (0, 0.5, 0.5)
and recessive models (0, 0, 0.5) (Durner et al., 1999). The
measure of the likelihood of linkage is the LOD score and we
considered LOD ≥ 3.3 to be statistically significant. Further we
performed per-family analysis for significant regions to identify
the families with COPD cases contributing the most to the LOD
score.
Identification of Variants in the Identified Regions
Next, we used exome-sequence data in ERF to identify rare
variants that may explain the identified linkage peaks. For this,
among all variants in this region we selected only variants
with predicted damaging effects on protein (missense and stop-
coding) based on the FunctionGVS column of the SeattleSeq
Annotation database2 from the National Heart, Lung and
Blood Institute (NHLBI) and with MAF < 0.05 in the general
population (1000 Genomes). As frequencies in a genetically
isolated population may be inflated or deflated due to genetic
drift (Pardo et al., 2005), we used the MAF from the general
population for filtering. We selected variants shared among
most (>50%) of the affected family members as candidate
variants.
A formal test of association was performed for the identified
candidate variants in each study – ERF, in samples with exome-
sequence (N = 636) and in exome-chip (N = 572) data, in three
RS cohorts (RS-I, RS-II, and RS-III), using the HRC imputed
data (N = 11,372), the LLS (N = 11,177), the VlaVla cohort
(N = 1,394) and the Hobbs et al. (2016) results (N = 11,797). For
this analysis, in ERF we used “seqMeta” package in R (Voorman
et al., 2013) to perform single-variant analysis, adjusted for age,
sex, and smoking status (current/past/never smoking). Logistic
regression analysis was used to associate the variants in the RS
and the VlaVla cohort, using SPSS software (Norušis, 1992) and
in LLS, using PLINK (Purcell et al., 2007), applying the same
models as used in ERF. Variants were excluded from the analysis
if the minor allele count was less than five in either the case
or the control category. Summary statistics for identified the
variants were extracted from the results of Hobbs et al. (2016).
A fixed-effects meta-analysis was performed with the summary
statistics from all studies using the “rmeta” package in R (Lumley,
2011).
2http://snp.gs.washington.edu/SeattleSeqAnnotation138/
Functional Look-Up of the Genes
We investigated the Ingenuity Knowledge Base for functional
annotation and look up of the genes, harboring the identified
variants (IPA, Qiagen bioinformatics) (IPA, 2015). Furthermore,
we consulted the Gene network tool (Fehrmann et al.,
2015), a bioinformatics database containing co-expression data,
functional predictions from gene ontology, Biocarta and the
KEGG to investigate our findings.
RESULTS
The general characteristics of the study samples are presented in
Table 1. All 27 families included in the linkage analyses in ERF
are depicted in Supplementary Figure S1. The affected relatives
were mainly smokers: 81.7% of the cases included in the linkage
analyses were current or ex-smokers. As shown in Table 2 and
Figure 1, we identified significant evidence for linkage of COPD
to chromosomes 15q14–15q25 (HLOD = 5.52), 11p15.4–11q14.1
(HLOD = 3.71), and 5q14.3–5q33.2 (HLOD = 3.49).
We next searched for rare, deleterious and shared variants
by most (>50%) of the affected family members in the three
identified regions mentioned above. In the linked regions of
chromosomes 5 and 15 we could not identify any variants
that passed mentioned filtering criteria. For the linked region
on chromosome 11, we identified two families that were
contributing most (LOD > 1) to the linkage score (Figure 2).
Exome-sequence data were available for 8 of 17 COPD
cases from these two families. We identified four missense
variants including rs116243978 (AHNAK), rs35169799 (PLCB3),
rs141159367 (SLC22A11), and rs146043252 (MTL5), shared
among five of the eight affected family members (Table 3).
Each of these variants was predicted to be highly pathogenic
(CADD > 15, PolyPhen > 0.98) which suggests their relevance
for the disease development. Of these four variants, one
(rs141159367 in SLC22A11) showed a significant association
(OR = 1.87, P = 0.002) with COPD in the meta-analysis (Table 4).
The variant rs146043252 in MTL5 showed a nominal association
signal (OR = 1.66, P = 0.04).
DISCUSSION
In this study, we found significant evidence for extensive linkage
of COPD to the chromosomes 15q14–15q25 (40.1 Mb), 11p15.4–
11q14.1 (73.9 Mb), and 5q14.3–5q33.2 (64.1 Mb). We were able
to identify four rare and predicted pathogenic variants under
the chromosome 11 peak, in plausible genes (AHNAK, PLCB3,
SLC22A11, and MTL5), shared by at least five family members.
One of these four variants, i.e., rs141159367 in SLC22A11, was
significantly associated with COPD in 9,888 cases and 27,428
controls (P = 0.002) while another variant (rs146043252 in
MTL5) showed nominal association with COPD (P = 0.04).
The finding of our family-based linkage analysis aligns with
that of large scale GWASs implicating the CHRNA3/5-CHRNB4,
and IREB2 region on chromosome 15q25 in COPD development.
This region is also associated with lung cancer, peripheral arterial
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TABLE 1 | General characteristics of the populations used in this study.
ERF RS Hobbs et al., 2016 Life lines Vlagtwedde/Vlaardingen
Linkage∗ Exome-chip Exome-sequence HRC imputed Exome-chip∗∗ GoNL imputed GoNL imputed
Number 142 572 636 11,372 12,165 11,177 1,394
Age, mean(sd) 59.7 (10.9) 51.7 (14.2) 48.5 (14.0) 65.1 (9.8) 58.4 (10.3) 48.2 (11.0) 52.7 (10.2)
Female gender, %(n) 59.9 (85) 56.8 (325) 61.8 (393) 58.0 (6,592) 44.5 (5,410) 58.6 (6,547) 46.3 (646)
COPD cases, %(n) 100 (142) 10.1 (58) 9.3 (59) 14.0 (1,588) 50.6 (6,161) 14.7 (1,647) 26.9 (375)
Never smokers, %(n) 1.4 (2) 27.1 (155) 29.4 (187) 35.3 (4,011) 1.7 (212) 40.7 (4,549) 30.2 (421)
Ex-smokers, %(n) 23.2 (33) 27.8 (159) 28.8 (183) 48.8 (5,546) 49.6 (6,037) 36.7 (4,104) 33.1 (462)
Current smokers, %(n) 58.5 (83) 45.1 (258) 41.8 (266) 16.0 (1,815) 45.0 (5,473) 22.6 (2,524) 36.7 (511)
∗ Information on smoking was missing for 16.9% (24) participants; ∗∗Full dataset reported in the Hobbs et al. (2016) meta-analysis. Information on smoking was missing
for 3.6% (443) participants. COPD, chronic obstructive pulmonary disease; ERF, Erasmus Rucphen Family; RS, Rotterdam study; GoNL, genome of the Netherlands.
TABLE 2 | Genome wide significant (HLOD>3.3) results of linkage analysis in the ERF study.
Cytogenetic
location∗
Start SNP End SNP SNP with highest
HLOD
Start position# End position# Dominant model
HLOD
Recessive model
HLOD
15q14–15q25 rs2004175 rs1402760 rs383902 39039593 79146817 4.24 5.52
11p15.4–11q14.1 rs1609812 rs7102569 rs626333 5247141 79184899 2.61 3.71
5q14.3–5q33.2 rs1366133 rs1432812 rs1154308 91114584 155274700 2.65 3.49
∗Region under the linkage peak; Start SNP – single nucleotide polymorphism (SNP) at the beginning of the corresponding region; End SNP – SNP at the end of the
corresponding region; HLOD, heterogeneity log of odds score; #Corresponding to the region from base to base of the linkage peak, based on the hg19 assembly.
FIGURE 1 | Logarithm of the odds (LOD) score plot for the regions at (A) chromosomes 5, (B) 11 and (C) 15. X-axis shows the chromosomal position in cM and the
Y-axis shows the heterogeneity log of odds score (HLOD) score. Red line represents HLOD scores for recessive and green line for dominant model. Dashed red line
represents the level of significance (HLOD = 3.3), while dashed black line represents the suggestive level (HLOD = 2).
disease, nicotine addiction and smoking quantity (Thorgeirsson
et al., 2008). The evidence in the literature on the role of smoking
in the genetic risk of COPD thus far is controversial. On one
hand, there is evidence to support that the variants in this
region, although implicated in both lung disease and smoking
behavior, are associated with COPD susceptibility, independently
of cigarette smoke exposure (Hardin and Silverman, 2014). On
the other hand, in a previous study we show that two variants,
previously associated with COPD in the CHRNA3/5 locus, were
associated with lung function measurements in ever-smokers, but
not in never-smokers (van der Plaat et al., 2017), which is in
line with the only longitudinal study on the relation between
the nicotine receptor variant and annual lung function decline
(Budulac et al., 2012). That study shows that carriers of the
nicotinic receptors variants are significantly less able to quit
smoking, leading to the lung function decline and, subsequently
to COPD. Similarly, for the chromosome 5 linked region, we
could not observe any shared rare variant. This region, known for
its associations with pulmonary function and airflow obstruction
(Hancock et al., 2010; Wilk et al., 2012) was recently associated
with COPD by the largest GWAS to date (Hobbs et al., 2017).
The HTR4 gene in 5q32 encodes a serotonin receptor involved
in depression and is strongly expressed in respiratory complex
neurons (Manzke et al., 2003).
However, the functional variants in these regions have still
not been confirmed. In our families, we could not identify rare
damaging variants shared between the cases in this region. This
may be explained if rare intronic regulatory variants play a key
role, which we could not investigate using the exome data. It is
unlikely that these linkage peaks are attributed to the common
variants which have small effects identified in GWASs, given the
very strong evidence for linkage of this region to COPD. Future
studies using whole-genome sequencing should investigate this
region further, ideally in never smokers. This emphasizes the
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FIGURE 2 | The two sub-families contributing most to the linkage peak on chromosome 11. Squares represent males and circles females. Cases are denoted in
black, known controls are denoted in gray and the family members for which we do not have chronic obstructive pulmonary disease (COPD) information are denoted
in white. Family members with dot in the middle are not included in Erasmus Rucphen family (ERF) study and for them only pedigree information was available.
Deceased family members are crossed. For cases with exome-sequence data used in the sharing analysis information on 5-year age range (in years) is provided.
TABLE 3 | Deleterious variants from chromosome 11q (missense, stop codon or CADD > 15) with a frequency in the 1000 genomes <0.05 that are shared by at least 5
cases.
Gene Variant 1 KG
MAF
ERF
MAF
Cytogenetic
band
Position
(hg19)
A1 A2 Carrier-HET Carrier-HOM Function CADD PolyPhen
AHNAK rs116243978 0.005 0.04 11q12.3 62286165 G C 5/8 0/8 Missense 15.55 1
PLCB3 rs35169799 0.023 0.08 11q13.1 64031241 T C 6/8 1/8 Missense 15.73 0.982
SLC22A11 rs141159367 0.0006 0.04 11q13.1 64323476 T C 5/8 1/8 Missense 18.25 1
MTL5 rs146043252 0.0002 0.04 11q13.3 68478487 G A 5/8 0/8 Missense 21 1
1 KG MAF – minor allele (A1) frequency (MAF) in 1000 Genomes – EUR; A1: effect allele; A2: alternative allele; Carrier-HET: number of heterozygote carriers within the
8 COPD cases of the two top contributing families of the chromosome 11 region; Carrier-HOM: number of homozygote carriers within the 8 COPD cases; Function:
predicted function of the variant; CADD: Combined Annotation Dependant Depletion score (>15 considered deleterious); PolyPhen: probability that variant is damaging.
need for integration of available genomic information into
more focused, candidate-gene based efforts to disentangle the
functional role of the chromosome 5 and 15 regions.
In the identified region of chromosome 11 we were able
to pinpoint four strong candidate genes for the association
with COPD, i.e., SLC22A11, AHNAK, PLCB3, and MTL5. The
most interesting finding is the rare variant in SLC22A11 (solute
carrier family 22 member 11), which encodes an integral
TABLE 4 | Results of association analysis with COPD.
Gene Variant β OR SE P N
AHNAK rs116243978 0.14 1.15 0.18 0.422 13,402
PLCB3 rs35169799 0.05 1.05 0.04 0.247 36,948
SLC22A11 rs141159367 0.63 1.87 0.20 0.002 18,562
MTL5 rs146043252 0.51 1.66 0.25 0.044 12,050
Meta-analysis of the ERF exome-sequence, ERF exome-chip, Rotterdam
Study – HRC, Hobbs et al. (2016) exome-chip, LifeLines – GoNL, and
Vlagtwedde/Vlaardingen cohort – GoNL results. In bold: significant results. β:
Regression coefficient estimates from logistic regression model regressing COPD
status on indicated variants, corrected for sex, age, and smoking; OR, odds ratio;
SE, standard error of the effect; P, p-value of the significance; N-sample size used
in the analysis.
membrane protein and part of the family of OATs, known
to mediate the absorption and elimination of endogenous and
exogenous organic anions and as such, are involved in the
pharmacokinetic, pharmacodynamic and safety profiles in a wide
range of drugs (Bosquillon, 2010). SLC22A11 (OAT4) is mainly
expressed in kidney and placenta. However, it is also shown
to be expressed in lung tissue, fibroblasts and T-lymphocytes
(P < 5 × 10−7), among other tissues/cells reported in the Gene
network (Fehrmann et al., 2015). In addition, in vitro SLC22A11
mRNA was absent in normal human bronchial epithelial cells,
but highly expressed in other bronchial cells models comprising
transformed cells (Endter et al., 2009). SLC22A11 in particular is
known to be a drug target for probenecid, a SLC22A11 inhibitor,
used in the gout prevention and to increase antibiotic blood
levels, yet its direct role in lung disease treatment is still unknown
(Bosquillon, 2010).
Our linkage analysis yielded different regions compared with
those identified earlier. However, the fact that both SLC22A11
and MTL5 variants were associated with COPD in our meta-
analysis confirms their role in COPD and makes them even more
interesting candidates. MTL5 (metallothionein-like protein 5)
encodes testis expressed metallothionein like proteins (TESMIN).
They are highly conserved, low-molecular-weight cysteine-rich
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proteins induced by and binding to heavy metal ions, and they
do not have enzymatic activity. They play a central role in the
regulation of cell growth and differentiation, and are involved
in spermatogenesis, differentially regulating meiosis in male
and female cells (Olesen et al., 2004). MTL5 was shown to be
involved in nicotinate and nicotinamide metabolism and is also
expressed in fibroblasts and lung tissue (P < 7 × 10−29), based
on the Gene network (Fehrmann et al., 2015). Metallothioneins
were additionally shown to protect cells against oxidative stress
damage and participate in differentiation, proliferation and/or
apoptosis of normal and lung cancer cells (Werynska et al., 2015).
The main strength of our study is the genetically isolated
family-based population, which can display increased frequencies
of some variants found at very low proportions in panmictic
populations. This allowed us to perform a genome-wide linkage
scan and identify rare coding variants. However, even though
we identified linkage of three regions to COPD, a limitation of
our study is the low power to explain the peaks at chromosomes
5 and 15, possibly due to the use of exome data. As intronic
regulatory variants may play a significant role, in the future,
faster and cheaper whole-genome sequencing will allow us to
improve identification of rare variants and our understanding
of their involvement in COPD. As our sample consists of high
percentage of current or ex-smokers, it is possible that we
are demonstrating genetic effects on smoking which further
affects the development of COPD. Nevertheless, we were able to
demonstrate a positive association, independent of smoking, of
two variants in the association meta-analysis comprising 9,888
cases and 27,060 controls. Yet, studies with very large sample sizes
utilizing mediation or mendelian randomization techniques are
needed to disentangle these relationships and confirm our results
in the general population.
CONCLUSION
Using the powerful genome-wide linkage scan in a Dutch genetic
isolate, we have confirmed the implication of the 15q25 region in
COPD and identified regions at chromosomes 5 and 11. Within
the region on chromosome 11 we identified four deleterious rare
variants shared between most of the affected family members
in AHNAK, PLCB3, SLC22A11 and MTL5. The variants in
SLC22A11 and MTL5 were significantly associated with COPD
in our meta-analysis. Further studies pooling large sample
sizes could confirm the role of the identified rare variants at
chromosome 11 in the general population. Similarly, large studies
utilizing whole-genome sequencing should further investigate the
role of linked regions in chromosomes 5 and 15 in COPD.
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